However, our in vivo data suggested that inhibition of AMPK/mTOR/ULK1 pathway using compound C failed to affect AD-MSCs survival as well as the combined therapeutic efficacy of AD-MSCs and apelin in experimental PAD. This evidence concerns the gene APLN and Alzheimer disease.